A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models

One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4(+)) associates with lower overall and disease-free survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Falgàs, Aïda, Pallarès, Victor, Unzueta, Ugutz, Céspedes, María Virtudes, Arroyo-Solera, Irene, Moreno, María José, Sierra, Jorge, Gallardo, Alberto, Mangues, María Antonia, Vázquez, Esther, Villaverde, Antonio, Mangues, Ramon, Casanova, Isolda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049335/
https://www.ncbi.nlm.nih.gov/pubmed/31248974
http://dx.doi.org/10.3324/haematol.2018.211490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049335/
https://www.ncbi.nlm.nih.gov/pubmed/31248974
http://dx.doi.org/10.3324/haematol.2018.211490

Ejemplares similares